Loading…
← CockpitCompetitor Analysis › ATTO Attovia Therapeutics, Inc.Open in the cockpit ↗

Attovia Therapeutics, Inc.ATTOCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 100
Mkt cap
$710M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$3.93M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$15.53
1D+4.5%
1W-7.2%
1M+10.6%
3M-23.2%
6M+1,324.8%
YTD+3,193.7%
1Y+539.1%
ATR %9.7%
Beta-3.13
52w lowhigh44.5% off high

What Attovia Therapeutics does

No business profile yet.

Attovia Therapeutics at a glance

Size Attovia Therapeutics (ATTO) is a United States Health Care company (Biotechnology) with a market value of $710M, the 2450th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.53 on 18 Nov 2026.

Performance Over six months the shares gained 1,324.8%, against -24.8% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.

Growth The operating margin is -5,945.5% (peer median -76.8%).

Valuation It trades at 220.7× enterprise value to sales against a peer median of 6.8× (2nd most expensive of 17).

Short interest Short interest is 3.5% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

01000200021 May 202621 Aug 202618 Nov 2026ATTO 1569Peer median 76
Six months, rebased to 100: Attovia Therapeutics against the median of its 20 peers (local-currency closes).

Attovia Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenue$1.44M$1.35M$0
Revenue growth———
Gross profit$473,000$546,000-$313,000
EBITDA-$84.6M-$66.4M-$41.2M
Net income-$78.9M-$60.9M-$45.0M
Free cash flow-$78.4M-$61.5M-$36.8M
Capital expenditure$430,000$2.31M$1.77M
Total debt$3.84M$5.26M$0

Quarterly statements and history in the cockpit →

Attovia Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%SLDB301333002038301520AURAKURA772999669887SNDXATTO6-month return →1-month return →
Up and to the right = strong over both horizons. Attovia Therapeutics is the large dot.

Attovia Therapeutics competitors and peer comparison

How Attovia Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Attovia Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureATTOPeer medianRank in peer set
1-month return+10.6%-7.1%2nd highest of 21
6-month return+1,324.8%-24.8%highest of 19
Distance from 52-week high-44.5%-47.7%9th highest of 21
Operating margin-5,945.5%-76.8%2nd lowest of 17
EV / Sales220.7×6.8×2nd most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a

Questions

Which companies are Attovia Therapeutics's closest peers?
The cockpit's peer set: Solid Biosciences (SLDB), Shaanxi Micot Pharmaceutical Technology (2335.HK), R&G PharmaStudies (301333.SZ), Prime Medicine (PRME), Apnimed (APMD), Beijing SL Pharmaceutical (002038.SZ), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Aura Biosciences (AURA).
Is Attovia Therapeutics expensive compared with its peers?
On ev / sales it trades at 220.7× against a peer median of 6.8×, 2nd most expensive of 17 in its peer set.
How has Attovia Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +1,324.8% against -24.8% for the median peer; over one year +539.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.